CRDF – cardiff oncology, inc. (US:NASDAQ)
Stock Stats
News
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]
Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]
Form 4 Cardiff Oncology, Inc. For: Dec 16 Filed by: Levine James E.
Form SCHEDULE 13G Cardiff Oncology, Inc. Filed by: COMMODORE CAPITAL LP
Form 4 Cardiff Oncology, Inc. For: Dec 12 Filed by: TANNENBAUM RENEE P
Form 4 Cardiff Oncology, Inc. For: Dec 11 Filed by: PACE GARY W
Form 424B5 Cardiff Oncology, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.